Antimuscarinic Discontinuation in Patients with Overactive Bladder in Nursing Homes: A Retrospective Study of Medicare Beneficiaries

被引：0
|
作者：
Rajender R. Aparasu
Sneha Sura
Jagadeswara R. Earla
Aki Shiozawa
Daniel B. Ng
Carol R. Schermer
机构：
[1] University of Houston,Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy
[2] Astellas Pharma Global Development,undefined
[3] Inc.,undefined
来源：
Advances in Therapy | 2020年 / 37卷
关键词：
Adherence; Antimuscarinic; Overactive bladder; Nursing home; Urology;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3584 / 3605
页数：21
相关论文
共 50 条
  • [41] Impact of coexisting overactive bladder in Medicare patients with osteoporosis
    Caplan, Eleanor O.
    Abbass, Ibrahim M.
    Suehs, Brandon T.
    Ng, Daniel B.
    Gooch, Katherine
    Kirby, Cindy
    Abbott, Paul
    ARCHIVES OF GERONTOLOGY AND GERIATRICS, 2018, 75 : 44 - 50
  • [42] A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder
    Phiri, Kelesitse
    Hallas, Jesper
    Linder, Marie
    Margulis, Andrea
    Suehs, Brandon
    Arana, Alejandro
    Bahmanyar, Shahram
    Hoffman, Veena
    Enger, Cheryl
    Horter, Libby
    Odsbu, Ingvild
    Olesen, Morten
    Perez-Gutthann, Susana
    Kristiansen, Nina Sahlertz
    Appenteng, Kwame
    de Vogel, Stefan
    Seeger, John
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (05) : 867 - 877
  • [43] ANTIMUSCARINIC PERSISTENCE PATTERNS IN NEWLY TREATED PATIENTS WITH OVERACTIVE BLADDER (OAB): RETROSPECTIVE COMPARATIVE ANALYSIS OF FESOTERODINE, SOLIFENACIN AND TOLTERODINE
    Sicras-Mainar, A.
    Rejas, J.
    Navarro-Artieda, R.
    Ruiz-Torrejon, A.
    Aguado-Jodar, A.
    Kvasz, M. G.
    VALUE IN HEALTH, 2012, 15 (07) : A458 - A458
  • [44] Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients
    Kay, GG
    Abou-Donia, MB
    Messer, WS
    Murphy, DG
    Tsao, JW
    Ouslander, JG
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2005, 53 (12) : 2195 - 2201
  • [45] Cost and resource utilization in frail patients with overactive bladder treated with mirabegron or an antimuscarinic
    Walker, D.
    Johnson, T. M.
    Kimura, T.
    Nimke, D.
    Jiang, B.
    Lozano-Ortega, G.
    Lockefeer, A.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2021, 69 : S140 - S140
  • [46] Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients
    Drinka, Paul J.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2006, 54 (06) : 1004 - 1005
  • [47] CLINICAL EFFICACY AND SAFETY OF FULL DOSE ANTIMUSCARINIC AGENT TREATMENT ON UNSATISFACTORY IMPROVEMENT OF SYMPTOMS AFTER LOW DOSE ANTIMUSCARINIC TREATMENT IN MALE PATIENTS WITH OVERACTIVE BLADDER: A RETROSPECTIVE MULTICENTER STUDY
    Shim, Myungsun
    Bang, Woo Jin
    Oh, Cheol Young
    Lee, Yong Seong
    Cho, Jin Seon
    JOURNAL OF UROLOGY, 2017, 197 (04): : E104 - E105
  • [48] Barriers to antipsychotic discontinuation in nursing homes: an exploratory study
    Azermai, Majda
    Vander Stichele, Robert R. H.
    Van Bortel, Luc M.
    Elseviers, Monique M.
    AGING & MENTAL HEALTH, 2014, 18 (03) : 346 - 353
  • [49] Patterns of Use of Antimuscarinic Drugs for Overactive Bladder: A Study of the Norwegian Prescription Database
    Mauseth, Siri Ann
    Spigset, Olav
    Skurtveit, Svetlana
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 66 - 67
  • [50] A 12-Year Retrospective Study of the Prevalence of Anticholinergic Polypharmacy and Associated Outcomes Among Medicare Patients with Overactive Bladder in the USA
    Campbell, Noll L.
    Hines, Lisa
    Epstein, Andrew J.
    Walker, David
    Lockefeer, Amy
    Shiozawa, Aki
    DRUGS & AGING, 2021, 38 (12) : 1075 - 1085
12345